期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 8, 期 2, 页码 213-220出版社
INFORMA HEALTHCARE
DOI: 10.1517/14712598.8.2.213
关键词
brain tumor; engineering; measles virus; retargeting; virotherapy
资金
- NCI NIH HHS [R21 CA123839, P50 CA108961, R21 CA 123839, P50 CA 108961, P50 CA108961-030002, R21 CA123839-02] Funding Source: Medline
Background: Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy. Objective: In this article the authors discuss potential applications of oncolytic measles virus strains as novel antitumor agents in the treatment of gliomas. Methods: Important aspects of measles virus development as an anticancer therapeutic agent including engineering, retargeting and combination studies with other therapeutic modalities are discussed. The translational process that led to the first clinical trial of an engineered measles virus derivative in patients with recurrent glioblastoma multiforme is also described. Results/conclusions: Oncolytic measles virus strains hold promise as novel antitumor agents in the treatment of gliomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据